Capsule endoscopy (CE), introduced in 2000 and FDA-approved in 2001, remains a valuable tool for diagnosing gastrointestinal (GI) lesions, particularly in areas inaccessible to traditional endoscopy. While CE offers non-invasive imaging and improves detection of small bowel diseases and obscure GI bleeding, its widespread use is hindered by limitations such as lack of therapeutic capabilities, inability to obtain biopsies, reliance on peristalsis for movement, and time-consuming image interpretation.
Trending
- Iterative Health Closes $77 Million Series C to Accelerate the Future of Clinical Research (Business Wire)
- Private Equity vs. Independent Medicine: When Wall Street Enters the Exam Room (Working Healthcare – the Podcast Fixing Healthcare)
- Artificial Intelligence Is Not the End of the Physician (JAMA)
- Charted: The most (and least) burned out physician specialties (Advisory Board)
- Growth, practice value and mergers: A strategic guide for physicians (Medical Economics)
- The potential ‘litigation wave’ headed for GI (Becker’s GI & Endoscopy)
- Groundbreaking new study shows real-time AI platform better at diagnosing cancer than biopsy (UMass Chan Medical School)
- Investigational endoscopic therapy maintains weight after GLP-1 discontinuation (GI & Hepatology News)
